Condition
Classical Hodgkin Lymphoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 8 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownA Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersNCT06870487 · 2025-05-08
TERMINATEDNUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursNCT05714553 · 2023-03-08
TERMINATEDStudy of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)NCT05008224 · 2021-10-07
COMPLETEDA Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerNCT04254107 · 2020-05-29
TERMINATEDLITT and Pembrolizumab in Recurrent Brain MetastasisNCT04187872 · 2020-01-10
TERMINATEDPhase Ib of L-NMMA and PembrolizumabNCT03236935 · 2018-08-27
COMPLETEDPhase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersNCT03212404 · 2017-09-20
ACTIVE_NOT_RECRUITINGNivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain CancersNCT03190174 · 2017-08-24
COMPLETEDCommon interventions
PembrolizumabDRUG2SasanlimabDRUG2BleomycinDRUG1brentuximab vedotinDRUG1CK-301 (cosibelimab)DRUG1CyclophosphamideDRUG1DacarbazineDRUG1DocetaxelDRUG1DoxorubicinDRUG1EtoposideDRUG1Fosifloxuridine NafalbenamideDRUG1L-NMMADRUG1LeucovorinDRUG1LITT + PembrolizumabCOMBINATION_PRODUCT1Nab-RapamycinDRUG1NivolumabBIOLOGICAL1PembrolizumabBIOLOGICAL1PF-08046032DRUG1PrednisoneDRUG1ProcarbazineDRUG1SEA-TGTDRUG1VinblastineDRUG1VincristineDRUG1
Leading sponsors
Trial status mix
TERMINATED4
COMPLETED3
ACTIVE_NOT_RECRUITING1
Phase mix
PHASE17
PHASE23
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.